SRSalud Rodríguez-Pallares

Salud Rodríguez-Pallares

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Salud Rodríguez-Pallares has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Innovative β-lactams and β-lactam/β-lactamase inhibitor combinations against carbapenemase-producing Enterobacterales

    by Jorge Arca-Suárez, Tania Blanco-Martín, Lucía González-Pinto, Salud Rodríguez-Pallares, Juan Carlos Vázquez-Ucha, Alejandro Beceiro, Concepción González-Bello, Germán Bou

    SUMMARY: The global dissemination of carbapenemase-producing Enterobacterales (CPE) represents one of the most pressing threats to modern antimicrobial therapy. The rapid worldwide expansion of these organisms has been driven by the emergence and successful dissemination of diverse carbapenemases belonging to Ambler classes A, B, and D, including KPC, OXA-48-like, and metallo-β-lactamases, such as NDM, VIM, and IMP. These enzymes severely compromise the activity of carbapenems, historically considered the cornerstone for treatment of severe infections caused by multidrug-resistant Gram-negative bacteria. In response to this growing challenge, substantial efforts in antibiotic discovery have led to the development of several novel β-lactams and β-lactam/β-lactamase inhibitor combinations specifically designed to restore activity against carbapenem-resistant Enterobacterales (CRE). This review provides a comprehensive microbiological overview of recently approved and investigational agents targeting CPE. We examine the structural and mechanistic features of key therapeutic options, including cefiderocol and multiple β-lactam/β-lactamase inhibitor combinations incorporating classical penicillin-based sulfone derivatives, diazabicyclooctanes, and cyclic boronates. Particular attention is given to the biochemical properties and inhibitory spectra of β-lactamase inhibitors, as well as the antimicrobial activity of novel β-lactams and β-lactam/β-lactamase inhibitor combinations against both isogenic strains and large collections of clinical Enterobacterales isolates. In addition, we discuss the emerging resistance mechanisms that may compromise the clinical effectiveness of these agents. Understanding the mechanistic basis of both activity and resistance is essential to guide their optimal therapeutic positioning and to inform the next generation of antimicrobial development aimed at combating the ongoing threat of CRE.

  • Open Access

    Relative inhibitory activities of taniborbactam and xeruborbactam against KPC variants conferring reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam

    by Salud Rodríguez-Pallares, Christophe Le Terrier, Tania Blanco-Martín, Roberto Rilo-Antelo, Cristina Elías-López, Lucía Sánchez-Peña, Carlos Molina-Cáceres, Gloria Pérez-Rodríguez, Lucía González-Pinto, Luis Martínez-Martínez, et al.

    The emergence of KPC variants associated with ceftazidime/avibactam resistance may also compromise the activity of other recently developed β-lactams, including cefiderocol and cefepime/taniborbactam. Xeruborbactam is a boronic acid β-lactamase inhibitor with potent activity against serine- and metallo-β-lactamases and is currently under clinical development in combination with cefiderocol. We evaluated the in vitro activity of cefiderocol/xeruborbactam against a panel of clinical Klebsiella pneumoniae isolates and isogenic Escherichia coli transformants (including both wild-type and porin-deficient backgrounds) producing KPC variants. Xeruborbactam and taniborbactam activities were compared using ceftazidime, cefepime, and cefiderocol as reporter substrates. Inhibitory activity was analyzed by determining the IC₅₀ values for both inhibitors against KPC variants. Most clinical isolates producing KPC variants showed increased MIC values and substantial cross-resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam. Cefiderocol/xeruborbactam retained potent activity against all clinical isolates, regardless of the KPC variant produced or the outer membrane permeability status. These findings were confirmed in wild-type and porin-deficient isogenic E. coli models, in which the combination of KPC variants and porin loss synergistically increased resistance to multiple β-lactams, while cefiderocol/xeruborbactam consistently restored susceptibility to wild-type levels. Comparative MIC analyses showed that xeruborbactam enhanced the activity of all β-lactam partners to a greater extent than taniborbactam. IC₅₀ determinations revealed a 17-fold to 73-fold greater inhibitory potency of xeruborbactam, which was maintained across structurally diverse KPC variants. Overall, cefiderocol/xeruborbactam exhibited potent activity against KPC-producing Enterobacterales, including isolates producing KPC variants associated with reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam.

  • Open Access

    Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales

    by Lucía Sánchez-Peña, Salud Rodríguez-Pallares, Tania Blanco-Martín, Gloria Pérez-Rodríguez, Pablo Aja-Macaya, Lucía González-Pinto, Inmaculada López-Hernández, Belén Aracil García, Alejandro Beceiro, Germán Bou, et al.

    We evaluated the activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against isogenic Escherichia coli and clinical Enterobacterales isolates producing broad-spectrum β-lactamases. Avibactam and ledaborbactam enhanced ceftibuten activity against transformants producing serine-β-lactamases. Ceftibuten/xeruborbactam was also active against VIM and some IMP producers. All combinations were active against OXA-48- and KPC-producing clinical isolates. Ceftibuten/xeruborbactam also retained activity against VIM-producing clinical strains. Susceptibility rates for MBL producers varied, depending on the CLSI or EUCAST breakpoints applied.


  • Open Access

    Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa

    by Lucía González-Pinto, Laura Monge-Olivares, Gloria Pérez-Rodríguez, Pablo Aja-Macaya, Lucía Sánchez-Peña, María Antonia Gomis-Font, Salud Rodríguez-Pallares, Tania Blanco-Martín, Lorena López-Cerero, Alejandro Beceiro, et al.

    We aimed to characterize OXA-1054, a novel carbapenem-hydrolyzing class D β-lactamase (CHDL) detected in a multidrug-resistant Pseudomonas aeruginosa clinical isolate. Antimicrobial susceptibility was determined by broth microdilution, and carbapenemase activity was confirmed by hydrolysis assays. Whole-genome sequencing via Illumina and PacBio platforms enabled comprehensive analysis of the resistome and plasmid architecture. The bla OXA-1054 gene was cloned in parallel with bla OXA-48 and bla OXA-198 into the pUCP24 plasmid. β-Lactamases were produced in P. aeruginosa PAO1 for comparative evaluation of the phenotypic impact of each. OXA-48, OXA-198, and OXA-1054 β-lactamases were purified and further subjected to steady-state kinetic analysis, and 50% inhibitory activity of β-lactamase inhibitors was determined. The clinical P. aeruginosa isolate ARGA00461 showed resistance to carbapenems and most β-lactam/β-lactamase inhibitor combinations and tested positive in carbapenem hydrolysis assays. Genomic analysis revealed that the P. aeruginosa isolate ARGA00461 carried a gene coding for a previously uncharacterized CHDL, designated OXA-1054, which is closely related to the OXA-372 enzyme of environmental origin. The bla OXA-1054 gene was located in a small (≈5 kbp) non-conjugative plasmid coexisting with a conjugative IncP plasmid, which likely facilitated its mobilization. Production of OXA-1054 in P. aeruginosa PAO1 conferred a broader spectrum of β-lactam resistance than other CHDLs. Enzyme kinetics confirmed carbapenem hydrolysis with catalytic efficiency comparable to OXA-48 and revealed higher affinity for cefepime compared to OXA-48 and OXA-198. Among the inhibitors tested, only avibactam demonstrated relevant inhibitory activity. OXA-1054 mediates broad-spectrum β-lactam resistance in P. aeruginosa , including carbapenems and β-lactam/β-lactamase inhibitor combinations.

  • Open Access

    Emergence of KPC-producing Pseudomonas aeruginosa in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam

    by Gloria Pérez-Rodríguez, Pablo Aja-Macaya, Lucía González-Pinto, Biel Taltavull, María Tarriño-León, María del Mar Gallardo-García, Tania Blanco-Martín, Salud Rodríguez-Pallares, Lucía Sánchez-Peña, Miriam Moscoso, et al.

    We report an outbreak of KPC-producing Pseudomonas aeruginosa in Spain, involving four patients and an environmental isolate recovered from a hospital sink. All isolates belonged to clone ST253 and exhibited difficult-to-treat resistance, including resistance to imipenem/relebactam and meropenem/vaborbactam. Genomic analysis confirmed a plasmid-encoded bla KPC-2 and OprD deficiency. Functional assays demonstrated synergy between KPC-2 production and porin loss on resistance to carbapenem/β-lactamase inhibitors. The findings highlight the clinical threat posed by KPC-producing P. aeruginosa .


  • Open Access

    Disarming carbapenemase-producing Acinetobacter baumannii : high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310)

    by Salud Rodríguez-Pallares, Michelle Outeda-García, Emilio Lence, Arianna Rodríguez-Coello, Lucía González-Pinto, Paula Guijarro-Sánchez, Gabriela Alejandra Báez-Barroso, Tania Blanco-Martín, Juan Carlos Vázquez-Ucha, Agustina Llanos, et al.

    Carbapenem-resistant Acinetobacter baumannii (CRAB) represents an urgent global health threat, with resistance primarily driven by carbapenem-hydrolyzing class D β-lactamases (CHDLs) such as OXA-23. Therapeutic options remain limited due to the scarcity of effective β-lactam/β-lactamase inhibitor combinations. Pilabactam (formerly ANT3310) is a novel diazabicyclooctane (DBO) β-lactamase inhibitor featuring a fluorine substituent that extends its activity spectrum, relative to approved DBOs like avibactam and relebactam, to include CHDLs. Pilabactam is currently in phase I clinical trials in combination with meropenem, and its activity and mechanism against CRAB remain incompletely defined. Using engineered A. baumannii strains producing individual β-lactamases, we show that pilabactam restores meropenem activity against serine β-lactamase producers, including difficult-to-inhibit CHDLs. This was corroborated in 68 whole-genome-sequenced meropenem-resistant clinical isolates, yielding MIC₅₀ and MIC₉₀ values for meropenem/pilabactam of 1 and 2 mg/L, respectively. Frequency of resistance studies in representative CHDL producers demonstrated suppression of resistance selection at 4× MIC. Kinetic analyses revealed that pilabactam inhibits OXA-23 via a two-step tight binding mechanism, with slightly higher inactivation rates (1.7 × 10⁴ M⁻¹s⁻¹) than that of durlobactam (3.5 × 10³ M⁻¹s⁻¹). Pilabactam also yielded a low dissociation constant ( K d ≈ 4 nM) and slow off-rate, indicating durable inhibition. Molecular dynamics simulations revealed the critical role of the fluorine substituent in forming stabilizing hydrogen-bonding and CH–F interactions within the tunnel-like OXA-23 active site. These findings identify pilabactam as a potent novel DBO supporting its development with meropenem for treating CRAB infections.


  • Open Access

    Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa

    by Lucía González-Pinto, María Antonia Gomis-Font, Gloria Pérez-Rodríguez, Tania Blanco-Martín, Salud Rodríguez-Pallares, Lucía Sánchez-Peña, Alejandro Beceiro, Germán Bou, Katy Jeannot, Antonio Oliver, et al.

    Cefiderocol/xeruborbactam is a novel β-lactam/β-lactamase inhibitor combination in which the siderophore-cephalosporin cefiderocol is paired with xeruborbactam, a broad-spectrum inhibitor that targets class A to D β-lactamases. We evaluated the contribution of Pseudomonas aeruginosa resistance mechanisms to cefiderocol/xeruborbactam susceptibility. A panel of 61 P . aeruginosa PAO1 derivatives was tested, including 20 knockout mutants representing key chromosomal resistance mechanisms (e.g., ampC overexpression, efflux upregulation, porin loss, iron uptake deficiency) and 41 transformants producing major circulating β-lactamases. Xeruborbactam was assessed in combination with cefiderocol and cefepime at 4 and 8 mg/L and compared with taniborbactam. Additionally, 99 cefiderocol-resistant clinical P. aeruginosa isolates were evaluated. Cefiderocol/xeruborbactam retained activity against most P. aeruginosa mutants with chromosomally encoded resistance mechanisms. However, the P. aeruginosa piuC- defective mutant yielded increased cefiderocol minimum inhibitory concentrations (MIC = 2 mg/L), which could not be restored by xeruborbactam. Xeruborbactam significantly increased the activity of cefiderocol against the majority of P. aeruginosa PAO1 transformants, including those producing PER-1, SHV-12, KPC Ω-loop mutants, or NDM variants. Cefiderocol/xeruborbactam was active against IMP-type MBLs (which only weakly hydrolyze cefiderocol), including xeruborbactam-resistant enzymes. Relative to taniborbactam, xeruborbactam-based combinations showed similar activity against P. aeruginosa PAO1 transformants, but with slightly higher MIC values when tested against metallo-β-lactamase producers. This MIC increase in xeruborbactam-based combinations was partly because of the constitutive MexAB-OprM efflux in the P. aeruginosa background, as confirmed with P. aeruginosa PAO1 efflux mutants. Importantly, xeruborbactam restored susceptibility in 78% of 99 cefiderocol-resistant P. aeruginosa strains, reducing the MIC 90 from 64 to 4 mg/L. Cefiderocol/xeruborbactam shows promising activity against P. aeruginosa .


  • Open Access

    Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations

    by Lucía Sánchez-Peña, Salud Rodríguez-Pallares, Pablo Aja-Macaya, Tania Blanco-Martín, Lucía González-Pinto, Gloria Pérez-Rodríguez, Christophe Le Terrier, Inés Portillo-Calderón, Esther Recacha, Cristina Riazzo, et al.

    Xeruborbactam is a broad-spectrum boronate-type β-lactamase inhibitor. We aimed to evaluate its activity in combination with meropenem and compare it with other β-lactam/β-lactamase inhibitor combinations against Enterobacterales. The following isolates were screened: (i) an isogenic collection of 94 Escherichia coli isolates producing β-lactamases under wild-type and low-permeability conditions, (ii) 300 genetically diverse clinical Enterobacterales isolates producing the three main carbapenemase types (KPC-like, OXA-48-like, and metallo-β-lactamases), and (iii) two collections of isolates producing mechanisms of resistance to β-lactam/β-lactamase inhibitor combinations, such as KPC variants or PBP3 insertions combined with metallo-β-lactamases (MBLs). The MICs of meropenem, meropenem/xeruborbactam, meropenem/vaborbactam, imipenem, imipenem/relebactam, cefepime, cefepime/taniborbactam, ceftazidime, ceftazidime/avibactam, aztreonam, and aztreonam/avibactam were determined by reference broth microdilution and interpreted following the European Committee on Antimicrobial Susceptibility Testing guidelines, using the breakpoint of the β-lactam alone for not yet approved combinations. Resistance mechanisms of all clinical isolates were analyzed by whole genome sequencing. Meropenem/xeruborbactam had the broadest spectrum against the isogenic collection, although higher MICs were noted for transformants producing IMP-23, SPM-1, and NDM enzymes (these latter only when produced under low-permeability conditions). Meropenem/xeruborbactam displayed the most potent activity against the collection of 300 clinical strains (MIC 50/90 ≤0.06/≤0.06 mg/L). Xeruborbactam restored meropenem activity against the strains carrying resistance mechanisms to β-lactam/β-lactamase inhibitor combinations, including strains producing KPC variants or MBLs in combination with additional chromosomal alterations (MIC range: ≤0.06–0.25 and ≤0.06–4 mg/L, respectively). Our findings highlight the potential of xeruborbactam in combination with meropenem as a promising treatment against carbapenemase-producing Enterobacterales, including strains with emerging resistance to other β-lactam/β-lactamase inhibitor combinations.


  • Open Access

    Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in Pseudomonas aeruginosa

    by Lucía González-Pinto, María Antonia Gomis-Font, Emilio Lence, Michelle Outeda-García, Tania Blanco-Martín, Salud Rodríguez-Pallares, Lucía Sánchez-Peña, Isaac Alonso-García, Juan Carlos Vázquez-Ucha, Alejandro Beceiro, et al.

    A wide variety of clinically observed amino acid alterations in the Pseudomonas aeruginosa chromosomal β-lactamase AmpC ( Pseudomonas -derived cephalosporinase [PDC]) are associated with increased resistance to cefepime, ceftolozane/tazobactam, or ceftazidime/avibactam, but their impact on cefiderocol resistance is unclear. We took advantage of a previously engineered collection of wild-type (PAO1) and iron uptake-deficient (PAO Δ piuC ) P. aeruginosa isolates producing 19 distinct PDC variants with substitutions in key catalytic regions. While most variants had moderate effects on cefiderocol minimum inhibitory concentrations compared to PDC-1, the E219K (Ω-loop) and L293P (helix H10) variants significantly affected cefiderocol activity. Kinetic studies revealed that both mutations improve cefiderocol hydrolysis through different enzymatic mechanisms compared to PDC-1 ( K m = 85.29 µM, k cat = 0.0036 s −1 , and k cat / K m = 0.00004 µM −1 s −1 ), leading to enhanced turnover in PDC E219K ( K m = 465.64 µM, k cat = 0.45 s −1 , and k cat / K m = 0.00096 µM −1 s −1 ) and improved affinity in PDC L293P ( K m = 2.69 µM, k cat = 0.0036 s −1 , and k cat / K m = 0.00135 µM −1 s −1 ). These mechanisms are also involved in resistance to ceftolozane and cefepime, identified as the preferred substrates for the E219K and L293P variants, respectively. Molecular dynamics (MD) simulation studies revealed that (i) rigidification of the Ω-loop in PDC E219K promotes optimal accommodation of the R 1 group of cefiderocol, enhancing nucleophilic attack by the catalytic serine; (ii) the less folded conformation of helix H10 in PDC L293P improves cefiderocol accommodation in the active site by establishing stronger hydrogen-bonding interactions with the R 2 group. Our findings demonstrate that the PDC β-lactamase may take advantage of the structural similarities between cefiderocol and other cephalosporins and accelerate hydrolysis by accommodating the E219K or L293P amino acid replacements.


  • In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC β-lactamase in Klebsiella aerogenes

    by Salud Rodríguez-Pallares, Tania Blanco-Martín, Emilio Lence, Pablo Aja-Macaya, Lucía Sánchez-Peña, Lucía González-Pinto, María Rodríguez-Mayo, Ana Fernández-González, Fátima Galán-Sánchez, Alejandro Beceiro, et al.

    We describe the in vivo emergence of resistance to ceftazidime/avibactam via modification of AmpC in a clinical Klebsiella aerogenes isolate during therapy with this combination. Paired ceftazidime/avibactam-susceptible/resistant isolates were obtained before and during ceftazidime/avibactam treatment. Whole genome sequencing revealed a differential mutation in AmpC (R148W) in the ceftazidime/avibactam-resistant isolate. Molecular cloning and structural studies confirmed the impact of this substitution, which affects the architecture of the H10 helix, on the evolved resistant phenotype.